Natural Alternatives | 10-Q: FY2026 Q1 Revenue: USD 37.73 M

Revenue: As of FY2026 Q1, the actual value is USD 37.73 M.

EPS: As of FY2026 Q1, the actual value is USD -0.05.

EBIT: As of FY2026 Q1, the actual value is USD 480 K.

Private-Label Contract Manufacturing

• Net Sales: $36,065,000 for the three months ended September 30, 2025, compared to $30,630,000 for the same period in 2024, representing an 18% increase.
• Gross Profit: $3,156,000 for the three months ended September 30, 2025, compared to $629,000 for the same period in 2024.
• Income from Operations: $1,803,000 for the three months ended September 30, 2025, compared to a loss of - $645,000 for the same period in 2024.

Patent and Trademark Licensing

• Net Sales: $1,665,000 for the three months ended September 30, 2025, compared to $2,520,000 for the same period in 2024, representing a 34% decrease.
• Gross Profit: $1,241,000 for the three months ended September 30, 2025, compared to $1,630,000 for the same period in 2024.
• Income from Operations: $712,000 for the three months ended September 30, 2025, compared to $997,000 for the same period in 2024.

Corporate Expenses

• Not Allocated to Segments: - $2,231,000 for the three months ended September 30, 2025, compared to - $2,188,000 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $4,023,000 for the three months ended September 30, 2025, compared to - $3,443,000 for the same period in 2024.
• Net Cash Used in Investing Activities: - $1,030,000 for the three months ended September 30, 2025, compared to - $301,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: $472,000 for the three months ended September 30, 2025, compared to $1,919,000 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to leverage its certified facilities to increase value for private-label contract manufacturing customers and develop relationships with additional quality-oriented customers. It aims to expand the commercialization of its beta-alanine patent estate through raw material sales and developing sales distribution channels in Sports Nutrition, Wellness and Healthy Aging, and Medical foods for its SR CarnoSyn® and TriBsyn™ product lines.
• Non-Core Business: The company is focused on improving operational efficiencies and managing costs and business risks to improve profitability.